|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LRRC75A-AS1 |
Gene summary for LRRC75A-AS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LRRC75A-AS1 | Gene ID | 125144 |
| Gene name | small nucleolar RNA host gene 29 | |
| Gene Alias | C17orf45 | |
| Cytomap | 17p11.2 | |
| Gene Type | ncRNA | GO ID | GO:0006139 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 125144 | LRRC75A-AS1 | S43 | Human | Liver | Cirrhotic | 1.93e-02 | -2.39e-01 | -0.0187 |
| 125144 | LRRC75A-AS1 | HCC1_Meng | Human | Liver | HCC | 9.14e-03 | -2.39e-01 | 0.0246 |
| 125144 | LRRC75A-AS1 | HCC2_Meng | Human | Liver | HCC | 1.93e-02 | -2.39e-01 | 0.0107 |
| 125144 | LRRC75A-AS1 | cirrhotic1 | Human | Liver | Cirrhotic | 9.14e-03 | -2.39e-01 | 0.0202 |
| 125144 | LRRC75A-AS1 | cirrhotic2 | Human | Liver | Cirrhotic | 1.93e-02 | -2.39e-01 | 0.0201 |
| 125144 | LRRC75A-AS1 | HCC1 | Human | Liver | HCC | 5.79e-22 | 5.22e+00 | 0.5336 |
| 125144 | LRRC75A-AS1 | HCC2 | Human | Liver | HCC | 1.18e-33 | 5.28e+00 | 0.5341 |
| 125144 | LRRC75A-AS1 | Pt13.a | Human | Liver | HCC | 1.93e-02 | -2.39e-01 | 0.021 |
| 125144 | LRRC75A-AS1 | Pt14.d | Human | Liver | HCC | 1.93e-02 | -2.39e-01 | 0.0143 |
| 125144 | LRRC75A-AS1 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 1.05e-29 | -9.88e-01 | 0.02 |
| 125144 | LRRC75A-AS1 | Adj_PTCwithHT_8 | Human | Thyroid | HT | 5.41e-22 | -1.01e+00 | 0.0267 |
| 125144 | LRRC75A-AS1 | PTCwithHT_1 | Human | Thyroid | HT | 4.50e-10 | -1.02e+00 | 0.0238 |
| 125144 | LRRC75A-AS1 | PTCwithHT_6 | Human | Thyroid | HT | 3.80e-36 | -1.04e+00 | 0.02 |
| 125144 | LRRC75A-AS1 | PTCwithHT_8 | Human | Thyroid | HT | 3.47e-25 | -1.01e+00 | 0.0351 |
| 125144 | LRRC75A-AS1 | PTCwithoutHT_2 | Human | Thyroid | PTC | 1.97e-29 | -1.02e+00 | 0.0419 |
| 125144 | LRRC75A-AS1 | PTCwithoutHT_4_2 | Human | Thyroid | PTC | 9.51e-07 | -1.08e+00 | 0.0455 |
| 125144 | LRRC75A-AS1 | PTCwithoutHT_7 | Human | Thyroid | PTC | 1.10e-12 | -1.08e+00 | 0.0381 |
| 125144 | LRRC75A-AS1 | male-WTA | Human | Thyroid | PTC | 4.66e-32 | -1.08e+00 | 0.1037 |
| 125144 | LRRC75A-AS1 | female-WTA | Human | Thyroid | PTC | 1.51e-15 | -1.08e+00 | 0.0726 |
| 125144 | LRRC75A-AS1 | nodule-WTA | Human | Thyroid | goiters | 1.51e-31 | -1.08e+00 | 0.0534 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Liver | Cyst |  |
| Lung | IAC |  |
| Lung | AIS |  |
| Lung | AAH |  |
| Lung | MIAC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |